TxCell develops personalized T cell immunotherapies for the treatment of inflammatory and autoimmune diseases.
Business Model:
Revenue: $2.7M
Employees: 11-50
TxCell was acquired by
Sangamo Therapeutics.
The acquisition happend on 2018-07-23.
Details of the transaction were not public
Address: Les Cardoulines HT1
City: Valbonne
State: provence-alpes-côte-d'azur
Zip: 06560
Country: FR
TxCell develops personalized T cell immunotherapies for the treatment of inflammatory and autoimmune diseases.
Contact Phone:
Contact Email:
Listed Exchange:
PA
IPO Date:
4/25/2014
Ticker Symbol:
TXCL
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 4/2014 | Venture Round | 1 | $21.4M |
Auriga Partners Auriga Partners |
11/2012 | Series C | 3 | $16.1M |
InnoBio Fund Seventure Partners Auriga Partners InnoBio Fund InnoBio Fund Seventure Partners Auriga Partners InnoBio Fund |
7/2015 | Equity | $8.7M | 1/2018 | Post-IPO Debt | 1 | $1.5M |
Bpifrance Bpifrance Bpifrance Bpifrance |
2/2017 | Post-IPO Equity | 3 | $11.6M |
Bpifrance InnoBio Fund Auriga Partners Bpifrance InnoBio Fund Auriga Partners |
2/2008 | Series B | 5 | $15.6M |
Auriga Partners Ardian Seventure Partners Innovation Capital Bioam Gestion Auriga Partners Ardian |
4/2014 | IPO | $22.2M |
|
11/2012 | Series C | $12.4M |
Auriga Partners Seventure Partners |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|